You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九洲藥業(603456.SH):2019年淨利預增55%-80%
格隆匯 01-21 15:52

格隆匯1月21日丨九洲藥業(603456.SH)披露2019年年度業績預增公告,經財務部門初步測算,公司預計2019年年度實現歸屬於上市公司股東的淨利潤為約2.44億元到約2.83億元,與上年同期相比,將增加8643萬元到約1.26億元,同比增加55.00%到80.00%。歸屬於上市公司股東的扣除非經常性損益的淨利潤與上年同期相比,預計將增加5970萬元到9898萬元,同比增加33.21%到55.06%。本期業績預增的主要原因:

(一)主營業務影響。

公司本期業績增長主要來自主營CDMO業務的增長。受藥品上市許可持有人制度(MAH)、新藥研發規模持續擴張等因素,公司2019年CDMO業務同比增長較快。同時,公司與國內外知名的創新藥原研公司如Novartis、貝達藥業等進行強強聯合的戰略合作,公司CDMO業務將持續穩健發展。

(二)非經營性損益的影響。

公司非經常性損益主要為政府補貼及遠期結售匯的影響,扣除所得税影響後的非經常性損益金額較上年同期增加2674萬元左右。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account